Verzenio_Medical_Necessity_Criteria
Defines prior authorization recommendation and medical necessity criteria for coverage of Verzenio (abemaciclib tablets) for FDA-approved indications (early breast cancer adjuvant, recurrent/metastatic breast cancer in women and men) and select other uses with supportive evidence (endometrial cancer, dedifferentiated liposarcoma). Specifies approval durations and exclusion of other uses.
Endometrial Cancer: Condition of approval and criteria were added to 'Other Uses with Supportive Evidence'.
Breast Cancer - Early: Duration of approval clarified to 2 years (total) and note added that indication applies to both women and men.
Breast Cancer - Recurrent or Metastatic: Option added for HER2-positive disease to be used with fulvestrant and trastuzumab after at least three prior anti-HER2 regimens.
Breast Cancer - Recurrent or Metastatic: Option added for use in combination with Inluriyo (imlunestrant tablets).
Liposarcoma: Condition of approval and criteria were added to Other Uses with Supportive Evidence.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.